In this lecture, we will provide an overview of how Intellia is leveraging its CRISPR-based technologies to develop novel, potentially curative therapeutics. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo investigational programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s investigational ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

*** Organizer will provide lunch. ***